Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...